CN1863798B - 2,4-二氧代-3-喹唑啉基芳基磺酰基脲 - Google Patents

2,4-二氧代-3-喹唑啉基芳基磺酰基脲 Download PDF

Info

Publication number
CN1863798B
CN1863798B CN2004800287913A CN200480028791A CN1863798B CN 1863798 B CN1863798 B CN 1863798B CN 2004800287913 A CN2004800287913 A CN 2004800287913A CN 200480028791 A CN200480028791 A CN 200480028791A CN 1863798 B CN1863798 B CN 1863798B
Authority
CN
China
Prior art keywords
compound
alkyl
halogen
alkoxy
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800287913A
Other languages
English (en)
Chinese (zh)
Other versions
CN1863798A (zh
Inventor
罗伯特·M·斯卡伯勒
黄沃林
安贾莉·潘迪
肖恩·M·鲍尔
张晓明
照中·J·贾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN1863798A publication Critical patent/CN1863798A/zh
Application granted granted Critical
Publication of CN1863798B publication Critical patent/CN1863798B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN2004800287913A 2003-10-03 2004-09-29 2,4-二氧代-3-喹唑啉基芳基磺酰基脲 Expired - Fee Related CN1863798B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50856403P 2003-10-03 2003-10-03
US60/508,564 2003-10-03
PCT/US2004/032921 WO2005032488A2 (en) 2003-10-03 2004-09-29 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Publications (2)

Publication Number Publication Date
CN1863798A CN1863798A (zh) 2006-11-15
CN1863798B true CN1863798B (zh) 2011-08-31

Family

ID=34421757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800287913A Expired - Fee Related CN1863798B (zh) 2003-10-03 2004-09-29 2,4-二氧代-3-喹唑啉基芳基磺酰基脲

Country Status (15)

Country Link
US (1) US7109332B2 (cg-RX-API-DMAC7.html)
EP (1) EP1668002B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007507551A (cg-RX-API-DMAC7.html)
KR (1) KR20060113700A (cg-RX-API-DMAC7.html)
CN (1) CN1863798B (cg-RX-API-DMAC7.html)
AT (1) ATE448222T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004278030C1 (cg-RX-API-DMAC7.html)
CA (1) CA2540214A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024093D1 (cg-RX-API-DMAC7.html)
ES (1) ES2334795T3 (cg-RX-API-DMAC7.html)
IL (1) IL174446A (cg-RX-API-DMAC7.html)
MX (1) MXPA06003618A (cg-RX-API-DMAC7.html)
PL (1) PL1668002T3 (cg-RX-API-DMAC7.html)
PT (1) PT1668002E (cg-RX-API-DMAC7.html)
WO (1) WO2005032488A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200605587B (en) * 2003-12-22 2008-02-27 Ajinomoto Kk Novel phenylalanine derivative
MX2007003836A (es) * 2004-09-29 2007-08-20 Portola Pharm Inc 2h-1,3-benzoxazin-4(3h)-onas sustituidas.
EA017402B1 (ru) * 2005-11-03 2012-12-28 Портола Фармасьютикалз, Инк. [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
WO2008124532A1 (en) * 2007-04-05 2008-10-16 Cv Therapeutics, Inc. Quinazolinone derivatives as aldh-2 inhibitors
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
CN101720324A (zh) * 2007-05-02 2010-06-02 波托拉医药品公司 [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
CA2936120A1 (en) 2009-01-19 2010-07-22 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
HK1209100A1 (en) * 2012-05-22 2016-03-24 基因泰克有限公司 N-substituted benzamides and their use in the treatment of pain
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
KR20150131233A (ko) 2013-03-14 2015-11-24 제넨테크, 인크. 치환된 트리아졸로피리딘 및 이의 사용 방법
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN107428696B (zh) 2015-02-16 2021-08-20 昆士兰大学 磺酰脲和相关化合物及其用途
US10179767B2 (en) 2015-05-22 2019-01-15 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3356360A1 (en) 2015-09-28 2018-08-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
BR112019007763A2 (pt) 2016-10-17 2019-07-02 Genentech Inc composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (en) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057037A1 (en) * 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors

Also Published As

Publication number Publication date
ATE448222T1 (de) 2009-11-15
IL174446A0 (en) 2006-08-01
JP2007507551A (ja) 2007-03-29
US20050107357A1 (en) 2005-05-19
AU2004278030B2 (en) 2010-07-01
PT1668002E (pt) 2009-11-25
KR20060113700A (ko) 2006-11-02
CN1863798A (zh) 2006-11-15
WO2005032488A3 (en) 2005-05-12
MXPA06003618A (es) 2006-08-11
EP1668002A4 (en) 2006-12-20
AU2004278030A1 (en) 2005-04-14
IL174446A (en) 2012-02-29
ES2334795T3 (es) 2010-03-16
EP1668002B1 (en) 2009-11-11
US7109332B2 (en) 2006-09-19
HK1093973A1 (en) 2007-03-16
CA2540214A1 (en) 2005-04-14
AU2004278030C1 (en) 2010-12-02
EP1668002A2 (en) 2006-06-14
DE602004024093D1 (de) 2009-12-24
PL1668002T3 (pl) 2010-02-26
WO2005032488A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
CN1863798B (zh) 2,4-二氧代-3-喹唑啉基芳基磺酰基脲
AU2005292314B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
AU2004279809B2 (en) Substituted isoquinolinones
JPWO2006057270A1 (ja) 含窒素３環化合物
EP2094272B1 (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
CN101534832A (zh) 作为血小板adp受体抑制剂的被取代的含氮杂环类化合物
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
HK1131058B (en) Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110831

Termination date: 20120929